Literature DB >> 12538717

A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Bernard P Leung1, Naveed Sattar, Anne Crilly, Morag Prach, David W McCarey, Helen Payne, Rajan Madhok, Carol Campbell, J Alastair Gracie, Foo Y Liew, Iain B McInnes.   

Abstract

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exert favorable effects on lipoprotein metabolism, but may also possess anti-inflammatory properties. Therefore, we explored the activities of simvastatin, a lipophilic statin, in a Th1-driven model of murine inflammatory arthritis. We report in this study that simvastatin markedly inhibited not only developing but also clinically evident collagen-induced arthritis in doses that were unable to significantly alter cholesterol concentrations in vivo. Ex vivo analysis demonstrated significant suppression of collagen-specific Th1 humoral and cellular immune responses. Moreover, simvastatin reduced anti-CD3/anti-CD28 proliferation and IFN-gamma release from mononuclear cells derived from peripheral blood and synovial fluid. Proinflammatory cytokine production in vitro by T cell contact-activated macrophages was suppressed by simvastatin, suggesting that such observations have direct clinical relevance. These data clearly illustrate the therapeutic potential of statin-sensitive pathways in inflammatory arthritis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538717     DOI: 10.4049/jimmunol.170.3.1524

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  117 in total

Review 1.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

2.  Molecular mechanisms in Behçet's disease.

Authors:  R Rajendram; N A Rao
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 3.  Do statins offer therapeutic potential in inflammatory arthritis?

Authors:  I B McInnes; D W McCarey; N Sattar
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

4.  Effect of Atorvastatin on the Disease Activity and Severity of Rheumatoid Arthritis: Double-Blind Randomized Controlled Trial.

Authors:  Karim Mowla; Elham Rajai; Ali Ghorbani; Mehrdad Dargahi-Malamir; Mohammad Bahadoram; Shooka Mohammadi
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 5.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 6.  Endothelial FAK as a therapeutic target in disease.

Authors:  Giovanni A Infusino; Jeffrey R Jacobson
Journal:  Microvasc Res       Date:  2011-10-06       Impact factor: 3.514

7.  Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes.

Authors:  X Palomer; L Calpe-Berdiel; J Verdaguer; J Carrillo; X Pastor; D Mauricio; F Blanco-Vaca
Journal:  Diabetologia       Date:  2005-06-30       Impact factor: 10.122

Review 8.  Regulation of different inflammatory diseases by impacting the mevalonate pathway.

Authors:  Robert Zeiser; Kristina Maas; Sawsan Youssef; Christoph Dürr; Lawrence Steinman; Robert S Negrin
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

9.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Authors:  E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

10.  Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.

Authors:  Robert Zeiser; Sawsan Youssef; Jeanette Baker; Neeraja Kambham; Lawrence Steinman; Robert S Negrin
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.